Teva Pharmaceutical Industries EV/EBIT TEVA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2018.

Today, Oct 23, 2026: 29.2×
8-year median: 5.5×
Against its 8-year history: 91st; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.8× to 52.7×
Peer median: 30.3×

Teva Pharmaceutical Industries' EV/EBIT is 29.2× as of Oct 23, 2026.

That is above its 8-year median of 5.5×, higher than on 91% of days in the last 8 years.

Over that time it ranged from 0.8× in Dec 2018 to 52.7× in Dec 2024.

The median for 10 healthcare stocks of a similar size is 30.3×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	29.2×	13.6×	30.7×
2025	17.6×	13.0×	50.7×
2024	52.7×	9.9×	52.7×
2023	9.6×	9.3×	10.0×
2022	8.3×	3.6×	9.2×
2021	4.9×	1.9×	5.6×
2020	2.8×	2.6×	3.9×
2019	3.3×	0.9×	5.1×
2018	0.8×	0.8×	1.2×

Against its peers

Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.

Company	EV/EBIT
TEVATeva Pharmaceutical Industries	29.2×
IQVIQVIA	27.3×
MDLNMedline	n/m
WATWaters	129×
IDXXIDEXX Laboratories	30.3×
AAgilent Technologies	31.1×
ONCBeOne Medicines	42.2×
HUMHumana	13.8×
EWEdwards Lifesciences	23.5×
ILMNIllumina	47.7×
BDXBecton, Dickinson and	22.1×
Peer median	30.3×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Teva Pharmaceutical Industries

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.